RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Clinical Trials

By participating in a clinical trial, you not only gain access to cutting-edge treatment & expert care, but you are participating in a potential medical breakthrough that could help many more people in the future.

Throughout the trial, you’ll be under the careful watch of leading physicians and research, ensuring your safety and well-being. If the medical treatment being tested in the clinical trial proves to be effective, you will be one of the first people to reap the benefits before it is released to the public.

Your participation today shapes tomorrow’s healthcare landscape.

Find a Clinical Trial

Filter Results By

  • Postal Code
  • Country
  • Trial Status
  • Type of Trial
  • Diagnosis

Sort by Trial name

26 Active Trials in 1104 Locations

Enter your Postal Code to find the nearest trial.

Sorry, that criteria does not currently fit any trials.

Currently Enrolling
Interventional

FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with:

• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)

See also the EPPIK Clinical Study for Children with FSGS and MCD.

Currently Enrolling
Interventional

FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with:

• Focal segmental glomerulosclerosis (FSGS)
• Minimal change disease (MCD)

See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.

Currently Enrolling
Interventional

The KIND study is testing the safety, efficacy, and pharmacokinetics of paricalcitol oral solution in participants of ages 0 to 9 years that have been diagnosed with Secondary Hyperparathyroidism (SHPT) associated with stage 5 Chronic Kidney Disease (CKD) receiving Peritoneal Dialysis (PD) or Hemodialysis (HD).

Currently Enrolling
Interventional

The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN2050) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

Currently Enrolling
Interventional

The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN1210 also known as ravulizumab or ULTOMIRIS ®) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.

Currently Enrolling
Interventional

The study is evaluating the safety and effectiveness of an investigational, targeted C3 inhibitor called pegcetacoplan in adults who have C3G or IC-MPGN recurrence after kidney transplant

Currently Enrolling
Interventional

The purpose of this study is to assess the efficacy and safety of twice weekly pegcetacoplan compared to placebo in patients with C3G or IC-MPGN, on the basis of a reduction in urinary protein levels.

Currently Enrolling
Interventional

This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.

Currently Enrolling
Interventional

JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.

Currently Enrolling
Interventional

A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2 inhibitor.

Currently Enrolling
Interventional

The purpose of this study is to evaluate the safety and efficacy of BION-1301 in adults with IgA nephropathy.

Currently Enrolling
Observational

Cure Glomerulonephropathy (CureGN) is a multicenter five-year observational study of glomerular disease patients.

Currently Enrolling
Observational

The Laboratory of Inherited Kidney Disease at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts, directed by Dr. Martin Pollak, seeks to identify genes that underlie the development of FSGS and similar diseases.

Currently Enrolling
Interventional

Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.

The study is ongoing at pediatric sites.

Currently Enrolling
Interventional

Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.

Enrollment Closed
Interventional

The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.

Currently Enrolling
Observational

El propósito de este estudio es recopilar datos de observación a largo plazo para ayudar a comprender la biología detrás del síndrome nefrótico.

Enrollment Closed
Interventional

The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Currently Enrolling
Interventional

This phase 3 trial will assess the efficacy and safety of sibeprenlimab administered SC once every 4 weeks as an add-on to standard of care (SOC) treatment (eg, angiotensin-converting enzyme inhibitors [ACEIs] and/or angiotensin receptor blockers [ARBs]). Furthermore, subjects who are on a stable dose of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy for IgAN, in addition to ACEIs and/or ARBs, may participate in the trial if treatment was initiated at least 3 months prior to
screening.

Currently Enrolling
Observational

Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.
Please consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.

Currently Enrolling
Interventional

A Phase II, Multi-center, Open-Label Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of R3R01 in Alport Syndrome Patients with uncontrolled Proteinuria on ACE/ARB Inhibition, and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.

Currently Enrolling
Observational

The Rare Genomes Project tiene como objetivo aumentar el acceso de las familias raras y no diagnosticadas a la investigación genómica, lo que permite a los pacientes acelerar directamente el ritmo del diagnóstico de enfermedades raras. Este proyecto fue diseñado para ser una asociación directa entre investigadores y pacientes, para que podamos comprender mejor sus condiciones.

Currently Enrolling
Observational

The TANGO study aims to create a large international network of centers to study glomerular disease (GN) recurrence after renal transplantation.

Currently Enrolling
Interventional

The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.

Currently Enrolling
Interventional

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Currently Enrolling
Interventional

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.

Headline decoration line

Careers

Explore career opportunities at NephCure, where passion meets purpose. Our dedicated team is committed to advancing research, supporting patients, and raising awareness for rare kidney diseases. Explore rewarding career opportunities today.

JOIN THE TEAM

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.